Belgian Journal of Paediatrics
Case series of Multisystem Inflammatory Syndrome in Children (MIS-C) after a SARS-CoV-2 infection
Vol. 24 No. 2 (2022), Case reports
Vol. 24 No. 2 (2022)

Case series of Multisystem Inflammatory Syndrome in Children (MIS-C) after a SARS-CoV-2 infection

Case reports
Published 2022-12-20 — Updated on 2023-01-17
Marlies Geeurickx
University of Leuven, Department of Paediatrics, Leuven and Department of Paediatrics, ZNA Jan Palfijn General Hospital, Antwerp, Belgium
Sietske Vermaning
Paediatric Intensive Care Unit, ZNA Queen Paola Children’s Hospital, Antwerp, Belgium
Thomas Crijnen
Paediatric Intensive Care Unit, ZNA Queen Paola Children’s Hospital, Antwerp, Belgium
Ine Gerard
Paediatric Intensive Care Unit, ZNA Queen Paola Children’s Hospital, Antwerp, Belgium
Els Vanderschraeghe
Department of Paediatrics, ZNA Jan Palfijn General Hospital, Antwerp, Belgium
Anke Raaijmakers
University of Leuven, Department of Paediatrics, Leuven and Department of Paediatrics, ZNA Jan Palfijn General Hospital, Antwerp, Belgium

Versions

PDF

Keywords

multisystem inflammatory syndrome in children and adolescents
MIS-C
paediatric multisystem inflammatory syndrome temporally associated with SARS-Co-V-2
PIMS-TS
COVID-19
SARS-Co-V-2
severe
cute respiratory syndrome coronavirus 2

Categories

How to Cite

Geeurickx, M., Vermaning, S., Crijnen, T., Gerard, I., Vanderschraeghe, E., & Raaijmakers, A. (2023). Case series of Multisystem Inflammatory Syndrome in Children (MIS-C) after a SARS-CoV-2 infection . Belgian Journal of Paediatrics, 24(2), 111–115. Retrieved from http://belgjpaediatrics.com/index.php/bjp/article/view/71 (Original work published December 20, 2022)
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

Multisystem inflammatory syndrome in children (MIS-C) is an entity in which children develop fever, raised inflammatory parameters, abdominal complaints and/or Kawasaki-like symptoms with signs of decreased cardiac function, weeks after a primary infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).  Complications include shock and coronary artery aneurysms. Our cases are in line with current evidence that clinical presentation of MIS-C is extremely variable, and evolution is favourable after treatment with intravenous immunoglobulins. Further research is necessary to substantiate current guidelines and to analyse possible links we have encountered between developing MIS-C and ethnic background, environment, and specific SARS-CoV-2 strains.

PDF